Wafik El-Deiry, MD, PhD, FACP an American Cancer Society Research Professor, is Associate Dean for Oncologic Sciences at the Warren Alpert Medical School and Director of the Legorreta Cancer Center at Brown University. He was previously Deputy Director & Program Leader at Fox Chase Cancer Center, Rose Dunlap Professor of Medicine & Chief of Hematology/Oncology, and Interim Director at Penn State Cancer Institute. Dr. El-Deiry joined University of Pennsylvania as Assistant Professor of Medicine & Genetics in 1994, was promoted to Associate Professor with tenure in 1999 & Professor of Medicine, Pharmacology & Genetics with tenure in 2005. He was an Investigator of the Howard Hughes Medical Institute from 1995-2004. He served as co-Leader of the Radiobiology & Imaging Program at the Abramson Cancer Center & Associate Director for Physician-Scientist Training in Hem/Onc at UPenn. He earned MD & PhD degrees at University of Miami & completed medicine residency & oncology fellowship at Johns Hopkins. Dr. El-Deiry discovered p21(WAF1) as p53 target gene, cell cycle inhibitor, & tumor suppressor that explained the mammalian cell stress response. This was the most highly cited original work published in Cell. He discovered TRAIL receptor DR5 as p53 target, & ONC201/TIC10 as TRAIL pathway, integrated stress response inducer & cancer therapeutic with efficacy in diffuse midline glioma & other tumors.Dr. El-Deiry has >500 publications & edited 6 books. He has served on editorial boards including as Associate Editor for the Journal of Clinical Investigation from 2007-2010 and Editor-in-Chief of Cancer Biology & Therapy from 2001 to 2019. He is active as an NCI grant reviewer, has served on ACS Council, lectures widely & is a highly cited researcher (H-index 128 in 2024 with > 103,000 citations in Google Scholar). He was named one of America's Top Oncologists by Consumer Res Council of America in 2008 & 2009. He is a member of Faculty of 1000 (Faculty Opinions), Interurban Clinical Club (President, 2013-2014), American Society of Clinical Investigation (ASCI) & Association of American Physicians (AAP). He organized international meetings & won 2009 Kuwait International Prize in Applied Sciences. He founded Oncoceutics in 2004 (acquired by Chimerix in 2021), p53-Therapeutics, and SMURF-Therapeutics. He became a member of the Johns Hopkins University Society of Scholars in 2014. He received the inventor of the year award from Brown University in 2022 and 2023. He is a practicing physician-scientist specializing in colorectal cancer treatment & precision oncology.